podcasts Ratings /ratings/en/research-insights/podcasts/2020-02-11-sp-pharma-dose-episode-34-more-color-on-ppd-s-rating-after-ipo content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

In This List

S&P Pharma Dose - Episode 34: More Color on PPD’s Rating After IPO

Leveraged Finance & CLOs Uncovered Podcast: A Deep Dive Into European Corporate Defaults

COMMENTS

2021 Global PC Shipment Forecast Raised To 0% From -7% Following Strong Expected Results In The Fourth Quarter Of 2020

COMMENTS

Credit FAQ: Anatomy Of A Credit Estimate: What It Means And How We Do It

COMMENTS

Why We See Ontario’s Electricity And Gas Regulatory Framework As Strong

Listen: S&P Pharma Dose - Episode 34: More Color on PPD’s Rating After IPO

In this episode of S&P Pharma Dose, senior healthcare analyst Ji Liu discusses his view on Pharmaceutical Product Development LLC (PPD) after its recent IPO on Feb. 5, 2020.

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back